Last reviewed · How we verify
Sitagliptin - DPP4i
Sitagliptin - DPP4i is a DPP-4 inhibitor Small molecule drug developed by Royal Devon and Exeter NHS Foundation Trust. It is currently FDA-approved for Type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents. Also known as: Januvia.
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals.
Sitagliptin is a small molecule dipeptidyl peptidase 4 (DPP-4) inhibitor used to treat conditions such as type 2 diabetes. It is classified as a DPP-4 inhibitor, a type of drug that works by inhibiting the action of the DPP-4 enzyme.
At a glance
| Generic name | Sitagliptin - DPP4i |
|---|---|
| Also known as | Januvia |
| Sponsor | Royal Devon and Exeter NHS Foundation Trust |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
DPP-4 inhibitors work by prolonging the action of endogenous GLP-1 and GIP, which are incretin hormones released after nutrient intake. By blocking their degradation, sitagliptin enhances glucose-dependent insulin secretion and suppresses glucagon secretion, leading to improved glycemic control. This mechanism is glucose-dependent, meaning it primarily works when blood glucose is elevated, reducing hypoglycemia risk.
Approved indications
- Type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents
Common side effects
- Nasopharyngitis
- Headache
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Pancreatitis
Key clinical trials
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
- IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics (PHASE1)
- Non-alcoholic Fatty Liver Disease and Its Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sitagliptin - DPP4i CI brief — competitive landscape report
- Sitagliptin - DPP4i updates RSS · CI watch RSS
- Royal Devon and Exeter NHS Foundation Trust portfolio CI
Frequently asked questions about Sitagliptin - DPP4i
What is Sitagliptin - DPP4i?
How does Sitagliptin - DPP4i work?
What is Sitagliptin - DPP4i used for?
Who makes Sitagliptin - DPP4i?
Is Sitagliptin - DPP4i also known as anything else?
What drug class is Sitagliptin - DPP4i in?
What development phase is Sitagliptin - DPP4i in?
What are the side effects of Sitagliptin - DPP4i?
What does Sitagliptin - DPP4i target?
Related
- Drug class: All DPP-4 inhibitor drugs
- Target: All drugs targeting DPP-4 (dipeptidyl peptidase-4)
- Manufacturer: Royal Devon and Exeter NHS Foundation Trust — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents
- Also known as: Januvia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing